1. Home
  2. CNX vs IMVT Comparison

CNX vs IMVT Comparison

Compare CNX & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNX Resources Corporation

CNX

CNX Resources Corporation

HOLD

Current Price

$35.97

Market Cap

5.0B

Sector

Energy

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$26.08

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNX
IMVT
Founded
1860
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.3B
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
CNX
IMVT
Price
$35.97
$26.08
Analyst Decision
Hold
Buy
Analyst Count
11
9
Target Price
$34.50
$29.13
AVG Volume (30 Days)
2.0M
1.6M
Earning Date
01-29-2026
02-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.02
N/A
Revenue
$1,930,542,000.00
N/A
Revenue This Year
$49.64
N/A
Revenue Next Year
$2.18
N/A
P/E Ratio
$17.88
N/A
Revenue Growth
40.99
N/A
52 Week Low
$27.00
$12.72
52 Week High
$42.13
$27.80

Technical Indicators

Market Signals
Indicator
CNX
IMVT
Relative Strength Index (RSI) 45.32 53.28
Support Level $34.81 $25.58
Resistance Level $36.66 $27.37
Average True Range (ATR) 1.10 1.18
MACD -0.06 -0.10
Stochastic Oscillator 54.30 45.48

Price Performance

Historical Comparison
CNX
IMVT

About CNX CNX Resources Corporation

CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: